干细胞之家 - 中国干细胞行业门户第一站

 

 

搜索
中源协和

免疫细胞治疗专区

欢迎关注干细胞微信公众号

  
查看: 20328|回复: 5
go

[已解决求助] 求助英文文献一篇 [复制链接]

Rank: 2

积分
251 
威望
251  
包包
64  

优秀会员 帅哥研究员

楼主
发表于 2011-11-6 09:58 |只看该作者 |倒序浏览 |打印
干细胞之家微信公众号
Correction of bilirubin conjugation in the gunn rat using hepatocytes immobilized in alginate gel bead as an extracorporeal bioartificial liver.Cell transplant 1993
) n/ z( ?- B/ x7 y7 D5 N* l' F2 Q+ X
链接:3 I8 u* n7 ?3 S; W, w  n
http://www.ncbi.nlm.nih.gov/pubm ... oartificial%20liver# M! O' ^4 N; h. O& v

Rank: 1

积分
0 
威望
0  
包包
818  
沙发
发表于 2011-11-6 13:03 |只看该作者
回复 cc1986 的帖子7 I( @' j/ U/ ~' k1 T+ |
* b/ d* T8 _% O2 ~
怎么传给你啊

Rank: 1

积分
0 
威望
0  
包包
818  
藤椅
发表于 2011-11-6 13:07 |只看该作者
Cell Biology and Toxicology. 1996;  12: 325-329.
  Y9 g. {( J7 H4 v9 t0 z© 1996  Kluwer Academic Publishers. Printed in the Netherlands / U8 X8 C4 \7 k2 P/ D6 W! f
Cell-based therapy of acute  liver failure: The extracorporeal bioartificial  liver ) i* p) X+ ?$ [$ o9 k; {) \/ ]  `
B. Fr6mond, A.  Joly, M. Desille, J.F. Desjardins,  J.P. Campion and B. C16ment
) m; \$ a' D4 i9 cDetoxication  and Tissue Repair Group, Institut National de la Santd et de la Recherche Mddicale,
# }' y2 k. W# }$ S1 m2 M% E0 F% H+ ]Rennes  I University School of Medicine,  CHRU Pontchaillou, Rennes, France + O# g. r) B/ E* a5 O
Accepted 11 July 1996 * ]9 a2 {6 Z5 \# {; c
Keywords: acute liver failure, bioartificial liver, cell-based therapy, hepatocytes
3 Z0 g% j9 Y5 U/ o- m$ Q7 AAbstract 8 ~6 Z* S* Q. `6 d
The need  for an alternative treatment  to orthotopic liver transplantation for acute  liver failure is a - e. G& m8 c( Y! z# k
major  issue, and systems capable of temporarily providing liver functions are being actively tested. 2 f2 f. O: X3 Q
Liver assist devices based on detoxication by dialysis or hemoperfusion through various membranes
6 t- _, M# R- T( `% Jor cartridges proved to be  inefficient  because of their lack of metabolic function. An extracorporeal / z; r5 a% o' W3 h' j. c" z0 A
hybrid  bioartificial  liver  might  be  an  appropriate  treatment,  since  it  can  provide  liver-specific : q& F3 i& p. J+ z- |1 P9 P- B8 V
functions, maintain  the patient alive, and allow spontaneous  recovery of the patient's  own  liver or ) }2 W/ l7 X+ h
act  as  a  bridge  toward  liver  transplantation.  Many  devices  have  been  proposed,  including  fiat ) Z4 M( c  Z+ g0 ?
culture  substrates,  hollow-fiber  bioreactors,  or  microcarriers,  using  xenogenic  hepatocytes  or 5 x; ^9 f5 x0 X6 E1 S0 K& K3 {( w& I4 J
hepatoma  cell  lines. Various  drawbacks  of  these  devices  led  us  to  attempt  to  develop  a  reliable
8 H; G5 }, U& y5 a* g0 K% t. lextracorporeal  bioartificial liver based  on  alginate bead-entrapped  hepatocytes. This  system was / F* W7 n9 Z5 B, W1 _3 T
used successfully for the correction of the Gunn  rat genetic defect, which results in lack of bilirubin " ]7 K' x5 j  J7 g
conjugation. The development of  this system for clinical purposes  requires large yields of  functional 6 q3 B$ N7 U& o: m7 y
hepatocytes. We  have  isolated  normal  porcine  hepatocytes by  collagenase perfusion  of the  liver. + V. U# {' e5 p3 J% l/ y0 q
Cells were immobilized in membrane-coated alginate gel beads, which were subsequently inoculated
$ e0 n8 s6 w' G, S+ l: hinto  a  bioreactor.  Porcine hepatocytes expressed  liver-specific functions at high  levels, particularly
0 s7 b7 R: A* n% k4 y1 u( N5 }protein  neosynthesis  and  enzymatic  activities  involved  in  detoxication  and  biotransformation
* q4 e- M7 `/ U5 cprocesses.  In  addition,  hepatocytes  entrapped  in  coated  alginate  beads  were  isolated  from
4 q+ s5 v3 g$ Qimmunoglobulins.  This  system  represents  a  promising  tool  for  the  design  of  an  extracorporeal
# j( W2 s& E# l6 V) A/ J; `bioartificial  liver in human beings.
/ b0 I3 l. u) L: G* sAbbreviations:  ALF,  acute  liver  failure; EBAL,  extracorporeal  bioartificial liver; OLT,  orthotopic
0 [1 P9 B7 x, r4 ]: yliver transplantation
* Q0 }( v2 u) S5 e2 pIntroduction
! \! e4 n* c4 b) a0 H$ y9 FAcute liver failure (ALF) remains a therapeutic 8 y5 h7 D+ a2 R8 ]( n
challenge.  Despite  recent  advances,  the  mor- ; ^7 D/ d$ b" _! y& B) t7 Z
tality  rate  is  high,  ranging  between  70%  and " R& `% ]7 j5 Z; w/ k
90%,  depending  on  both  the  age  and  the 0 w6 {$ v- G! M, a* G0 e
etiology  (Hoofnagle  et  al.,  1995).  Orthotopic
2 R( J, @2 b0 J* k5 K% yliver  transplantation  (OLT)  is  the  only  cur-
( \  s1 T8 x7 Irently effective treatment,  but  it is a major and 6 T: C  }3 d! [9 V( {0 N& i' ^
costly  surgical  procedure  which  requires  life- 326 7 V. q0 n& _6 P; P
long  immunosuppression  and  is  associated * K3 _+ U# L: }6 P
with  a  significant  morbidity  and  mortality. # y' {5 L$ G( V8 b7 ~
Furthermore,  by  removing  the  patient's  own
( ?& Z; X5 z6 s+ u# nliver,  OLT  prevents  any  opportunity  of  a
& q. j6 A* G+ u# {5 zspontaneous  hepatic  recovery.  Finally, scarcity
& N& B! G( t, _6 L) z! }of liver  grafts  is  an  important  limiting  factor. - x4 I: S1 m" Z* c. u/ G
There  is  therefore  a  striking  need  for  alterna-
. _% n5 _7 W( J1 z8 Ative treatments. , z  [& J; R4 P9 W
The  disappointing  results  of  the  first- 5 U& i6 q# {6 b" F, }' ]
generation  liver assist devices based on dialysis 1 W; P6 A: J  X/ o* ?
or hemoperfusion  through various membranes 1 D  k/ n7 \7 r
or  cartridges  have  suggested  that  the  restora-
: n7 `9 A, G/ H! Z1 Ption  of hepatic metabolic  functions  is required
& X; r4 C( h8 b: Zfor efficient treatment  of ALF. The best way to
/ Y; e3 W' K+ ?3 I2 h) l$ I, pkeep  alive patients  with ALF,  and  to  preserve 0 Y. S0 h$ h: Z$ R, S! q4 I: P
their  neurological  potentialities  without  OLT, $ A: K' p, H4 Q4 j/ ?6 d& z
would  be  to  treat  them  with  a  hybrid,  bio- 3 P  P; T% m/ x( t8 ?
artificial  system  capable  of  providing  appro- - O4 E, i0 E3 [3 r( K- @0 c9 _
priate  hepatic  functions  of synthesis, biotrans- ; i$ z2 u3 |  H, v( `
formation,  and  detoxication.  Such  a  system
' X) K- G. W* h, q. K1 Icould  allow  spontaneous  liver  regeneration  or
$ o# p/ [6 v" U' eact as a bridge toward OLT in good conditions.
- ]6 C. i3 x' g( P1 j8 qFulminant hepatic  failures from viral,  toxic,  or
( D* j' d+ q  L# Mdrug  origin would  be  the main  indication  for ; n9 f7 _' q% u" l9 l
this therapy. Other  indications include primary
6 r& {1 E2 Z$ }% U3 ]7 Ononfunctioning  grafts  after  OLT  or  acute  de- ; P# X' j2 f: E
compensations  of chronic  liver insufficiency. 0 {2 Y0 A( w! C
The  design  of  such  bioartificial  devices  is
4 U- B$ V/ R  k  q( O7 M# u) vcomplex.  They  should  contain  hepatocytes, , A1 U, r# E8 N9 J- ]" B
which  are  highly  differentiated  and  metaboli- / b* R( k8 c, X; k# E, O$ C9 s
cally active cells and are dependent  on cell-cell
* b) E7 }8 o4 \  m7 O; iand  cell-matrix  interactions  for  their  survival 4 r/ x( w  z/ l% G
in  vitro.  Due  to  the  scarcity  of  human  grafts, 1 _( ]( N! b" U( U2 F% H
these  hepatocytes  may  not  be  normal  hepato-
9 V9 N* Y+ T9 e3 qcytes  of  human  origin.  The  other  sources  of # Z* A- P+ a+ [/ x) b
hepatocytes  include  either  allogenic  human 3 i  T2 [6 k. N9 \" r7 t
immortalized  and/or  transformed  cell  lines  or 1 Y( V. o# Y6 K8 ^
xenogenic  hepatocytes.  In  order  to  maintain   C3 \2 U; q, l0 o) U" K
these  cells  functional within  an  optimal  envir- 4 S. ]7 p3 C' K& S" U
onment  for  metabolic  exchanges,  hepatocytes
+ `+ N( v( M8 Y2 l7 w" \must  be  in  close  contact  with  the  patient's ; W( h6 z1 w3 O' Y" N
circulation  through  an  immumoisolating ) C7 N0 E- o3 W
hemocompatible  barrier  that  prevents  any
# V( o& k2 t0 Rinteraction  with  blood  cells  and  immuno-
% h; Q% L7 P1 ]9 E3 ]8 \globulins. The extracorporeal  bioartificial  liver
3 ?* I3 h% }7 {- T(EBAL)  must  be  safe  for  the  patient.  The
) D9 M1 b1 r$ J0 V9 @; xminimum  number  of  normal  hepatocytes  in
. t- S5 N; M4 d( n6 Y9 Dan efficient EBAL has been estimated  to repre-
7 A( _# A2 Z% _* `2 {* f9 Jsent at  least  10% of the  total  pool  of a  normal & C9 j  Y  d2 }1 N  Q
liver. Cell density should be  as high as possible 2 x+ E$ a2 b; y$ q6 q& Z( ?5 I- Y5 Z
so as to obtain efficient mass  transfer processes
# x1 \4 G9 O. mwithout  the  need  for  a  bulky  device.  Finally,
4 W: |& [2 I' o' xthe  clinical situation  of ALF  requires  immedi-
3 B* f# V; \7 y9 @9 _* Yate  availability of the  EBAL,  and manufactur-
4 k0 a3 j1 ~3 m9 U! s# A/ @. Jing,  storage,  and maintenance  of EBALs must
0 k9 Y/ }6 c, Jmeet  with  industrial  and  economic  gold  stan-
6 f3 k. R6 Q  U& a; vdards.   v5 e0 l0 B3 M0 [
Several  authors  have  developed  bioartificial 4 A# |# P% V1 |% K
liver assist devices.  Dialysis with  a  suspension # U) }' K, o4 s4 v0 {# K& }3 I
of hepatocytes  is  the  simplest  one.  This  is  the
/ J8 h( U% S* Q% f4 H3 U5 k- xfirst  system  to  have  been  used  in  a  human
( S9 f2 }/ [% W, L; Ybeing  (Matsumura  et  al.,  1987).  However,
; n" q; F+ _" w, T$ @4 ghepatocytes  are  anchorage-dependent  for  their 6 ^; Z0 _9 W7 s; S% @
survival and  function,  and  such  a  system has  a
. g$ {- L/ ]* {6 Mlimited  efficacy.  To  ensure  hepatocyte  adhe- ) T! P7 q. i. ?3 C' H+ P4 t& s& `
sion,  a  monolayer  culture  can  be  established $ m1 j) |- O: ^7 O- \
in  a  bioreactor  with  a  large  internal  surface.
4 E; X9 C: q' _) f& f. x. _Such  a  bioreactor  is  based  either  on  stacked
5 r: g8 l! K/ pplates  (Takahaski  et  al.,  1992)  or  on  hollow 6 r! C) \! v9 i  g0 F/ W% X
fibers  (Gerlach  et  al.,  1994;  Jauregui  et  al.,
7 b2 x; r" \# E( R1995).  In  both  cases,  the  potential  outputs  of
4 }) n* {& T3 P2 D% O! g. u1 Fthese  two-dimensional  systems  are  very  low,
5 s8 a! ?% r' C0 R6 R/ B" wdue  to  the  small  numbers  of  cells  compared
* A6 ?" G; ^3 H; M; ]with  the  very  large  exchange  surface.  The
" o5 ?* f7 K  Z  ~4 Mefficiency of hollow-fiber  bioreactors  has  been
8 J- r% w" d( z1 G/ ?$ Genhanced  by  seeding  hepatocytes  in  collagen   R2 B" m. G" T. G
gel  matrices  inside  the  fibers  (Nyberg  et  al., ) G+ Z5 c$ t2 y6 S  p) X
1993).  Promising  results have been  obtained  in
  `9 j/ K; s1 \+ E6 Idogs with D-galactosamine-induced  ALF  (Sie-
  d/ H5 C, P& `) u/ X9 u( Ilaff  et  al.,  1995). However,  the  major  draw-
, B/ \6 h1 e7 `8 Q% p  y' ebacks  of  these  hollow-fiber-based  bioreactors / m8 ?) }; r3 H; Z4 u, k
are  time-consuming  preparation  and  the  im-
  R. ~# W; E+ Y# fpossibility  of  long-term  preservation.  These
* R1 h7 Q4 g- H& E" w! Z4 _conflict with  one  of the major  requirements  of , E: g. S- q8 l0 Z, x0 i
EBAL  -  the  absolute  need  for  emergency
/ w) c# J: u- c) H  q' W9 Davailability.
# o/ R) d1 o" [7 I, Y4 mIn  order  to  fulfill this  requirement,  the  bio- : [. y7 W/ f$ n/ S" R# v0 j: H
reactor  must  be  prepared  and  checked  in
1 S5 b% i, B& _: I5 {8 I4 Badvance,  before  storage.  Specifically,  the most 4 P& e* R" f0 ]- r/ ^0 A
time-consuming  stage,  i.e.,  preparation  and 327
* p* r- A. e* d5 e- o: `& ]0 Dimmobilization  of  hepatocytes,  must  not  be ! q0 n; [( Z( J6 T
done  extemporaneously  prior  to  use.  It  has 9 |# A2 R( ]' @3 D, A2 V+ Z! c" g
been  shown  that  cryopreservation  of hepato- 2 o: q6 R- R& s4 o1 k
cytes is possible and safe  (Chesn6 et al.,  1993). - I) Y+ S: u* o" f7 n5 @; f. G
A  prototype  meeting  this major  specification - j1 H: I1 }5 {/ p2 H# D
has  been  designed  by Demetriou  and  collea-
" N' S3 k( _4 f- lgues  and  tested  in  rats  (Arnaout  et  al.,  1990),
  ^- [0 d# c) U% Z4 Qdogs  (Rozga  et  al.,  1993),  and  humans 3 o# V9 U4 N% w" ^1 s$ W9 }2 @
(Demetriou  et al.,  1995). This system contains
# V5 z; M- W* S, \& d* ecryopreserved  pig  hepatocytes  attached  to
. }" ~, F# i7 e  Jmicrocarriers.  Microcarriers  are  inoculated ( s3 q  T2 r' T0 Y9 v6 }8 r
into the extracapillary space of a microporous ( {) d1 A+ I; `0 ^. B1 U
hollow-fiber  bioreactor  (pore  size  0.2  gm).   ]* q. V* ^# M$ i
Plasma  from  a  plasma  separator  flows  in  the
* H. N  C) }) F3 T- J* \6 Nintracapillary space,  filters  through  the mem-
) K( p5 C) Z5 K+ Fbrane pores,  and  interacts directly with hepa-
$ e+ B4 q' D0 t- \0 w8 xtocytes  before  being  reinjected  into  the
4 F' k+ t( A6 O: r5 z& e/ Spatient's  circulation.  A  charcoal  column  is " O$ Q9 i# P8 X0 N+ Y1 }  I
inserted  in  the  loop.  The  membrane  has  no ) V3 A! t- Z: R9 t$ B( a+ t5 G' C
perm-selectivity,  large macromolecules  includ- 5 C( `9 K- s, x  V! Z& f+ s9 v0 M7 R9 `( s
ing  immunoglobulins being  able  to  permeate.
7 t. n$ l; W, c; I0 v: aEighteen patients have been treated with such a 2 o  y/ q3 X' F- ?2 e8 B
device  (Chen et al.,  1995), either for  fulminant
" t( |+ g, `& w5 R: ~9 f1 ghepatitis (group A, n = 11) or for acute decom-
4 O' m5 F; g* x' b& [pensation  of  chronic  hepatopathy  (group  B, * R7 p  h8 J  Y& a% L7 h' ]
n = 8). In group B, only two patients underwent 2 B2 a  X5 |' ?+ J/ Z
OLT;  all  others  died.  In  group  A,  all  the ' x4 D. o, E! M" v9 a' O
patients have undergone OLT, but their neuro- 4 S4 D! _3 Q) m$ Q* y/ ^9 Q
logical status improved during the EBAL treat- 9 F  x- t0 E7 g3 u6 [0 ^) `
ment.  However,  a  charcoal  hemoperfusion
( A# v4 a, e  U  d) ~8 a* Halone may also improve the neurological status 7 e/ r) {" l* J, S! K; c/ |
of patients with ALF  (O'Grady et al.,  1988). A 5 d  s* S+ k9 K, O; z' `7 I% P
major  drawback  of  this  system  is  the  direct + q* T$ @9 J" S1 t
contact between human plasma and pig hepa-
+ q) A. r, X* Ztocytes.  Although  pig  hepatocytes  are  less 0 ]: P8 n# Z' {6 x, k, n2 ^) L
vulnerable to the cytotoxicity  of human natural 4 B0 B. F1 f" d# E/ G4 |
antibodies  than  other  cells,  particularly endo-
8 O3 [# d/ l1 a8 [* mthelial  cells  (Fujioka  et  al.,  1995),  this  direct
/ t" Z' ?1 a! i2 U: z) Dcontact  is  likely  to  be  deleterious  for  the
" l" v' n5 o' |$ D4 hbioreactor  in  some  cases.  Complete  immuno- 8 I' @$ I$ }0 }: J7 L
isolation  of xenohepatocytes  appears  manda- . {% B+ n) C6 Y9 M6 x9 Z
tory.
. o, A3 R8 t. F( @: q) `% j. wImmunoisolation of xenohepatocytes can be
+ R' c9 g' C. t+ K" |; V: }achieved in a different design of bioreactor that 6 G  s( A& b* f; {) O
is  based  on  hepatocytes  embedded  within / k# D5 U% ?3 T0 v+ b6 ^, a
hate-entrapped  hepatocytes % ?; ^: d* ^4 G% C2 d' B
Figure 1. Schematic diagram of  a bioreactor  containing porcine
: S: [$ I6 G* P3 W" x) E! Xhepatocytes  entrapped in calcium alginate beads.
. ^  U7 j! O( \! h6 Y. Y  d; \3 K9 Bmicrospheres made of a semipermeable matrix
! n; w8 b9 H  u1 }# i/ c5 t4 U7 f: Uof  calcium  alginate. We  have  developed  an ; W3 @! N& u2 B8 N: l( a" g
EBAL  based  on  this  new  concept.  Plasma ) P: h- A5 s6 F" @. g& P/ E/ u
flows  inside  the  bioreactor  in  direct  contact
, i$ I: c+ X* f! E! b8 n! Lwith  beads,  without  the  interposition  of  any
( m0 G  S; v# v6 Sartificial membrane,  since hepatocytes have no
0 ^# K' X! `0 f) D9 l$ Bdirect  contact  with  plasma  (Figure  1).  These
' b8 x! a* }5 Z6 Sbeads  exhibit  a  very  large  surface-volume 1 V6 E) H+ `: R+ ?3 }
ratio.  Such  a  system  allows  optimal  mass
! d/ l" q3 f, J" ]- G+ t7 Jtransfer  conditions,  with  a  high  cell  density
1 [1 q2 W. ?, {" Y2 r(up  to  107 hepatocytes/ml)  and minimal dead 3 Z, B5 O" _. E: i: P2 Y' P
spaces. We have been  able  to  demonstrate  the $ s  V7 ?7 i  L; E6 y; ?8 ~
efficacy of  this device in an experimental model 5 q; u' C  ~% R! _/ C  L5 ~
of  impaired  liver  function  in  Gunn  rats
- n- w) G5 y9 X(Fr6mond et al.,  1993). The homozygous Gunn
/ N& G! [2 p$ ^- D- t/ D2 nrats possess  a congenital deficiency of bilirubin
, p. v$ ~) {2 d9 M% `- e% Fconjugation. When maintained  in  EBAL,  im- 7 U( l2 z( C0 g
mobilized normal  rat  hepatocytes  did  not  ex- 328   L8 M6 P  L! j: }, Z7 B
hibit  any  loss  of viability for  at  least  6  h  of # t. }4 N3 Y. ]* L0 ^
extracorporeal circulation.  In the test group of ; M1 L  H5 O3 V3 h; f' [5 R
Gunn  rats,  the  concentration  of  total  biliary ' ]6 i9 V  R2 }. i, W( H  U# B
bilirubin  conjugates  increased  rapidly,  reach-
; ?) I5 N( T3 e- g$ N8 x3 Ping more  than  200  gmol/L  after  3 h  in  some ; m/ c1 f+ `) n3 C0 v
cases,  as compared with less than  1 gmol/L in 4 }! N; M' n) Q
the control group.  Recently, we have designed 5 a2 ]2 v. b0 h0 s$ c- I* N( K
a  similar bioreactor  for experimental purposes
5 f$ D4 g% s$ h+ r9 m9 H2 Lwith large mammals  and  future potential clin- , q8 i/ t0 J" M7 |# G' Z
ical use  (Joly et  al.,  accepted,  in press).  Survi-
0 W# m% b% K8 S. O' Q( P1 n5 g/ G9 Ival,  proliferation,  and  functions  of  porcine
; q, S' K( Z1 _# X" M. R/ N; ihepatocytes were  evaluated  in primary mono- % o6 o4 t/ e6 W& u6 K7 n/ C" X
layer culture  and  after  embedding  in  alginate ; ~% d5 U9 n- Q  o$ {$ w
beads  that  were  subsequently  coated  with  a
; ?" n9 K' ]& f2 s  ~5 }; Pmembrane,  produced  by a  transacylation reac- ( r% b& l6 U! [* ?: V
tion between alginate and albumin, in order  to
4 [/ f9 z8 [8 |- ?) oimprove  the  immunoisolation.  Disruption  of   w/ _, l# r  o2 I6 l4 \1 F
whole  pig  livers  by  collagenase  perfusion  al- 5 d* J0 `2 e/ t. x6 |* M
lowed up  to 8 x 101° hepatocytes, with a viabi-
& G: [, j6 f8 g0 flity  greater  than  90%,  to  be  obtained.
0 [: W0 c/ x$ DHepatocytes  in  monolayer  culture  or  en- 6 d8 C9 |  N: ?5 |) R
trapped  in  coated  alginate beads  survived  for # z% @" C: {' T. B
about  10  days,  secreted  proteins,  and  main- ; |# }9 L4 H0 z$ T' Q) t, r
tained at high levels several  phase  I  and phase
6 ]- A& y) Y; V" i9 n, D  wII  enzymatic  activities,  namely,  ethoxy- 8 H- U3 v: {8 A. B8 t+ z0 D4 d2 e' t
resorufin-O-deethylase,  oxidation  of nifedipin & C6 ?( V! g  m! |' b" x! z0 T
to  pyridine,  phenacetin  deethylation  to
7 q3 k# K- V* y  kparacetamol,  glucuroconjugation  of paraceta-
, V- E- b2 \  r) ?mol, and N-acetylation of procainamide. Typi-
) `& Y) `/ W- B6 Z6 J$ P1 h4 ncal  features  of  mitosis  and  [3H]thymidine ' N. m% U8 v% J' {# s
incorporation showed that porcine hepatocytes 3 F1 e7 X$ T( Q$ {) l. C* g
proliferated spontaneously in both monolayers 5 z4 t) h) W/ W! b% A
and beads.  The  immunoisolating properties  of ! y9 u- }* y/ B: H, A
the  coated  alginate  beads  were  checked  by * i5 m2 ~4 L" e
incubating  entrapped  HLA-typed  human $ z4 o/ i4 |3 @3 D: x( t' {+ q  }
lymphocytes with  specific  anti-HLA  immuno- : k2 B- t4 b6 l& Q
globulin  G  and  complement:  no  lysis  was
: j: a. v( W) r$ x1 p/ zobserved,  in  contrast  to  controls  (non-
9 g! ~3 J# X' U0 L; x* D3 i% I  \entrapped  lymphocyteS)o In  addition, we have 9 Z) R8 T/ Z6 {' `8 _; f
recently demonstrated  that cryopreservation of
% f9 D% ]$ @" V; O, x9 U1 y8 \hepatocytes  immobilized in alginate beads  did
; o9 t7 K; p# ]4 `( F4 Enot result in marked alterations of  liver-specific ' M* k. e- f. h: B: P! k
functions  (Guyomard  et  al.,  accepted,  in
4 n( c1 g8 W3 e: ~press).
& v. q# x+ j9 K2 n1 zAll of the devices described above use hepa- + v; U/ _) @' B9 g: F
tocytes of animal origin, mainly from  the pig. / p2 |* I$ G# Y# R
Many  initial  problems  have  been  solved
3 ]+ I( S- I7 `0 s) D1 `8 \+ ~: {through  the use of animal hepatocytes,  includ- 8 E* N- v7 B. ?: f( n( X
ing  isolation,  culture,  immobilization,  func-
% {5 b8 u6 ]9 i5 m' S7 W- ytional studies,  and cryopreservation. The main
: b$ Y4 ?- O8 ~/ Iproblems  that  remain  to  be  settled are  first of
) S" Y9 ]. h  M7 f% V2 O) Mimmunological nature  and  second  the  risk of   U9 z4 X, }: d0 a
xenogenic infections.  The  immunological pro- ! \8 P' `( v* ?& s0 q  |, r& a
blem  has  been  solved  in  part  by  the  use  of , Q2 f2 x& W9 q; p
alginate beads, which prevent the  risk of dele-
4 N# m" C( R5 A3 [6 x; zterious  effects  of human  plasma  on  the  cells. 9 u% Z% T1 S# U! T; F
However,  both  the  function  and  immuno-
! z$ d; z3 G: l! i" N, hgenicity of xenogenic  neosynthetized proteins / e2 K# T# B+ S3 v1 J
in  human  beings  remain  unknown.  Only  few 4 B' u8 K+ r: T" B- `
data  are  available  concerning  this  important
6 j' o, y# g6 F# V$ B# w7 Q' V; W* Sissue.  A  baboon-to-human  liver  transplanta-
$ M5 ~2 \0 g% i; H+ Ction  was  recently  performed  by  T.E.  Starzl
4 ?, ~! \4 z; {and  colleagues  (Starzl  et  al.,  1993).  In  that
$ F5 s2 q3 F  |2 Q$ r# y* Ycase,  the  function  of  the  baboon  proteins 5 H, \& I; ~! J3 r2 O* D6 Q: p
synthetized by  the graft  seemed  to be  normal,
- I) M4 S( j* t9 ebut their immunogenicity has not been investi-
7 e' w: `3 i( s; X2 r" M! Agated,  due  to  immunosuppressive  drugs  and ; z2 d$ J$ m- O7 ]' y( r, ?
the patient's brief survival. The risk for patients 9 z( H. C4 N+ v& Q8 l  s  K
and  public  health  of  xenogenic  infections, + A8 Q& j4 [/ z" E- s3 t
particularly retroviral, is a major concern. This 8 O7 S- Q2 h8 m$ W
risk  would  probably  be  minimized  by  using 8 P0 `, _, d, I7 {! J
hepatocytes  from  pigs,  which  are  phylo-
9 ~: o9 u0 x$ T; J; vgenetically more  distant from  the human  spe-
& F. X' Q# ]- W, j& h9 N8 Ycies than are primates (Chapman et al.,  1995).
9 C+ _, O9 l; n4 X4 w  j, [  v1 s* R$ ^In order to overcome the problems raised by ( D5 G  l8 E" m
the use of xenohepatocytes in EBAL, Sussman - c6 L2 O+ H  f+ i
and  colleagues  have  designed another  type of 1 d* z& Z& T0 R: |3 w4 U5 _
liver  assist  device,  based  on  a  hollow-fiber
" g1 L8 C* c" m6 t: w/ t. w4 i. Hbioreactor  containing  cells  from  the  human $ Y: n5 F" t* h! c: Q
C3A cell line (Sussman et al.,  1992). This well-
- O8 N3 E2 ?1 X# Q1 D* I, ?differentiated cell line was isolated from a child
( e, y/ M7 {$ n; x* G0 ^& B- {hepatoblastoma.  Cells  are  inoculated  in  the
5 V. L+ a' s$ K; [4 e* |4 qextracapillary  compartment  of  a  bioreactor - Q- ]+ n% W# W6 @, b
and are allowed to grow until confluence for a , `3 U& W$ y- E' C; D
few weeks,  after which cells survive within the - h& u2 ?0 H$ K) q
bioreactor  for  several  months  in  vitro.  This
' r- s8 N+ V; q0 Uallows  immediate  availability for  clinical use,
6 p, Y$ r5 U) }+ sat  the  cost  of  important  culture  and  storage / s% |0 O) L! O/ ]
units capable  of maintaining hundreds  of bio- 1 P+ p; `4 U! k- Q! ?& E+ q1 z
reactors  for  several  months.  Such  an  EBAL 329 6 K! ^% b( S/ Y# w4 s8 M( ^% ?
contains  a  significant mass  of cells,  and  could
( O# a3 a2 `. Wthus  potentially  represent  a  very  efficient de- & A6 K+ d, e0 p8 ^9 E
vice. A multicentric study  is  in progress  in the ! [( ~8 @, i, r! j8 f% X& c5 k
United States  and Europe.  Preliminary results , W  j+ i2 `: L! Z1 F/ S) g$ F
from  17 patients have been published recently
9 H( B6 R% I0 D3 m, [(Sussman et al.,  1994; Ellis et al.,  1994), but no ) G5 H  F% t# D( M3 G
definitive conclusion can be drawn. The major
1 |% L( ^2 s3 adrawback  of  this  system  is  the  use  of  C3A , _$ v% G$ K; a' o8 K5 x
neoplastic cells in the EBAL. The risk of  tumor 5 I: g2 S+ N1 T) e
graft  and/or  induction  in  the  treated  patients 0 N, @; R4 ]8 b, G* P
has been suggested. Moreover, it is known that
" v$ N( T+ X) a: n9 i3 Y8 othe  functional  capacities  of  transformed ) O0 u2 W& Y8 V2 p" M! N0 h: Y4 v6 ?
hepatoblastoma  cells  are  much  lower  than ( |- B6 @( V5 w6 Y) D1 v/ X  |3 ~5 b
those of freshly isolated normal hepatocytes. " y7 o( a1 D$ O9 t
In  conclusion,  there  are  many  solutions  to ) N0 d/ s' k9 z8 I+ `  K0 }
the  various  problems  raised  in  the  use  of  an
' q3 t* v+ l: h5 Z0 r2 Jextracorporeal  bioartificial  liver  for  the  treat- / P+ k8 n* K5 K
ment  of ALF.  Each  solution  displays  advan- ( J( g7 J+ X& T
tages  and  disadvantages,  but  the  existing 6 V8 E- ?& E5 P9 o
results  clearly show  that  cell-based therapy  of
$ w0 [0 X- n' E5 [& QALF  is feasible and  should be  available  in the 0 k7 {9 ^3 |0 z. H4 l1 N# {
near future. 3 N  r0 f. {) k& J2 C: o4 L
Acknowledgments
- c  G3 k: u( z/ [This work was  supported by  INSERM  and by
* q* a; |0 L1 w4 B. \grants  from  Minist~re  de  la  Recherche
3 c% h# L, @  @. Q0 P4 a+ a(DSPT5-ACC-SV No.14;  Biotechnologie) and 0 x" P2 u- E8 w' N5 q. y) X
Fondation de l'Avenir (ET5.144).   w' k, k1 Z4 w2 B9 H; w7 X
References
+ E  F" f: ~  D4 z/ `0 eArnaout WS,  Moscioni AD,  Barbour  RL,  Demetriou  AA.
3 }+ B" _$ `2 ^. U2 m7 `. k2 MDevelopment of bioartificial liver;  bilirubin conjugation  in , B9 v* ^* s" \& Q( h9 W  H
Gunn rats.  J Surg Res.  1990;48:379-82. # ?% r: R' V! T* T4 A) V/ Z( m
Chapman LE, Folks TM,  Salomon DR, Patterson AP, Egger-
3 p! o* o" I( j+ o" uman TE, Noguchi PD. Xenotransplantation  and xenogeneic 3 C0 d' j4 e2 V9 d
infections. N Eng J Med.  1995;333:1498-501.
% f4 \6 n. ?8 H& H& S) ]- JChen S, Watanabe FD, Rozga J et al. Clinical  experience with a
( [" u4 o4 w+ ebioartificial  liver (BAL). Hepatology.  1995;22:203A. 5 V2 g1 P/ G* x' p  K' g
Chesn6 C, Guyomard C, Fautrel Aet al. Viability  and function
4 O( R% y! _" a9 {8 h. x* \in primary culture of adult hepatocytes from various animal * G1 P$ Q& m. \3 i$ l% |
species  and human beings after cryopreservation. Hepatol- 9 p- d9 g6 g& N2 S7 t8 `
ogy. 1993;18:406-14. 3 q& b0 a5 M( [6 g  f# @
Demetriou  AA,  Rozga  J,  Podesta  Let  al.  Early  clinical & i' K6 [; I) E% u2 f4 E
experience with a hybrid bioartificial  liver. Stand J Gastro-
3 \" k, G8 w) _* y8 ^6 C; ?# denterol.  1995;30(supplement  208):  111-7.
2 I4 \6 O* I$ I& ~' EEllis A  J, Wendon J, Hughes R  et  al. A  controlled trial  of the ' h+ \8 ]. n4 g$ M6 m8 c
Hepatix extracorporeal liver assist device  (ELAD) in acute   c9 w: v! l# q5 ^3 A8 ]
liver failure. Hepatology.  1994;20:140A. ' j, A. u+ |0 ^! t: z) L8 Q
Fr6mond B, Malandain C, Guyomard C, Chesn6 C, Guillouzo
. a. t* X3 J2 R5 x- |' bA, Campion JP. Correction of bilirubin  conjugation  in the
$ q. ?/ R* Q$ r& ]! T: k1 r# i. S; Y  {% IGunn  rat  using hepatocytes  immobilized in  alginate  gel * b% I% S( [3 a% b- R
beads  as  an  extracorporeal  bioartificial liver.  Cell Trans- 2 x& N2 }. W# b0 b4 S
plant. 1993;2:453-60. . `8 L) v; ?" C9 r2 m( r+ V1 `* k
Fujioka H, Cramer DV, Yasunaga C et al. Differential patterns
- l# e9 W& h. Fof reaction of human natural antibodies to pig hepatocytes
( Y( u  e+ {9 Uand vascular endothelium. Liver Transplant Surg.  1995;1: 4 P6 A, P- K9 }: V" m
85-93. ) m6 O8 L; B6 q& ^. d6 @3 u8 R
Gerlach JC, Encke J, Hole O, Muller C, Courtney  JM, Neuhaus , ~- Y) C3 n* A& q- w" Q( e2 h: }
P. Hepatocyte culture between  three dimensionally  arranged
; t8 E. d+ r5 {% ]5 Y  abiomatrix-coated  independent  artificial  capillary  systems ' K: j* s7 j* X) w. D! [
and  sinusoidal  endothelial  cell  co-culture  compartments. 5 C# C8 w) q; D2 p3 y, M4 s/ |4 T% k' a
Int J Artif Organs. 1994;17:301-6. ( Z" g6 X. y- v) c& `6 \
Hoofnagle JH, Carithers RL, Shapiro C, Ascher N. Fulminant   L" c, f4 [, U
hepatic  failure:  summary  of  a  workshop.  Hepatology.
9 f7 I& X3 g- I' [, b% l' a$ w1995;21:240-52.
- t, u' B2 |% j2 SJauregui HO, Mullon CJP, Trenkler D  et al.  In vivo evaluation " b& s+ q, y" m3 G
of a  hollow fiber  liver assist  device.  Hepatology.  1995;21: 9 a6 j& g# s1 v( J0 J8 d: ]$ h2 l
460-9.
$ L% B0 M7 m# t& mMatsumura KN, Guevara GR, Huston H  et al. Hybrid bioarti- 2 s2 y4 g* {: [6 X. J! J
ficial  liver  in  hepatic  failure:  preliminary clinical  report.
& x% N) w5 M% b" I: zSurgery.  1987;101:99-103. ) t8 B8 y# \* d8 L) C* J! j
Nyberg  SL,  Payne WD,  Amiot  Bet  al.  Demonstration  of
' E6 D; K& ~; n, l5 i' U: F7 r5 Zbiochemical function by extracorporeal xenohepatocytes in : s7 r; W' Q- R3 G
an anhepatic animal model. Transplant  Proc.  1993;25:1944-
0 L+ |" d0 j' J9 |  ?5. : C- @8 l/ u) w" w* e
O'Grady JG,  Gimson AES,  O'Brien CJ,  Pucknell A,  Hughes
; T2 J, M! U  T1 C& @RD, Williams R.  Controlled trials  of charcoal hemoperfu- # l9 h' O. _! p$ |' E5 [% U
sion  and  prognostic  factors  in  fulminant hepatic  failure. ; x2 ], O* I+ A3 Y8 X$ l) n
Gastroenterology.  1988;94:1192-8.
' X+ D) v4 Y# h7 s4 n; R/ MRozga J, Williams F, Ro MS et al. Development of a bioartifi- ( N+ y1 y, i8 p
cial liver: properties and function of a hollow-fiber module ; ?! b& g* ?! @) M5 [* c
inoculated with liver cells. Hepatology.  1993;17:258~5.
0 s! Z' x* K( A! V$ K# k( USielaffTD, Hu MY, Amiot B, Rollins MD, Rao S, McGuire B.
  B( r' g! @& h- IGel-entrapment  bioartificial  liver therapy in galactosamine . X( Q( q  y" p6 t- _( E( Y0 d) _
hepatitis.  J Surg Res. 1995;59:179-84.
( x% _% S7 i5 X) [3 FStarzl  TE,  Fung  J,  Tzakis  Aet  al.  Baboon-to-human  liver
4 l8 ?7 b7 `5 y0 }( Ctransplantation. Lancet. 1993;341:65-71.
9 {; n' [1 C: R3 R  g* o' ^Sussman NL,  Chong  MG,  Koussayer T  et  al.  Reversal  of 9 d5 ^! _8 G/ A  s
fulminant  hepatic failure  using  an extracorporeal liver assist : _  j7 w/ u! _# M# o& V4 O
device. Hepatology.  1992;16:60-5. 0 E& H4 N* {% M" r, H$ X
Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix 8 l5 ^* r) {' M4 i% C1 ^
extracorporeal liver assist device: initial clinical experience.
9 L! M$ X7 T/ F; f# Z% C- YArtif Organs. 1994;  18:390-6.
: a+ X2 n/ L% T2 h9 t1 W1 GTakahaski M, Matsue H, Matsushita Met  al. Does  a porcine
7 i* E8 j* G2 |3 M  v8 ghepatocyte hybrid artificial  liver  prolong  the survival  time of
/ R$ B! B  p; B+ {anhepatic rabbits? Asaio J.  1992;38:M468-72.
7 e- D2 y% Z/ B) B( NAddress for correspondence." Benjamin Fr6mond, Groupe DRT,
( F1 ~, G( u" S2 x% M  ^INSERM, 2 avenue L6on Bernard, 35043 Rennes, France
已有 1 人评分包包 收起 理由
细胞海洋 + 5 欢迎参与文献互助

总评分: 包包 + 5   查看全部评分

Rank: 1

积分
0 
威望
0  
包包
2  
板凳
发表于 2011-11-6 13:40 |只看该作者
本帖最后由 hnsdlgl 于 2011-11-6 13:40 编辑 5 f. q/ V+ j; D  G) o* }
  c' B! `3 V( N* S' W: P
到下面下载
附件: 你需要登录才可以下载或查看附件。没有帐号?注册
已有 1 人评分威望 包包 收起 理由
细胞海洋 + 2 + 5 欢迎参与文献互助

总评分: 威望 + 2  包包 + 5   查看全部评分

Rank: 2

积分
251 
威望
251  
包包
64  

优秀会员 帅哥研究员

报纸
发表于 2011-11-6 22:15 |只看该作者
回复 hnsdlgl 的帖子2 ~2 f7 Q7 \8 C# p/ U1 ~

1 g( I! D: l* |( D' q' c* p谢谢

Rank: 2

积分
251 
威望
251  
包包
64  

优秀会员 帅哥研究员

地板
发表于 2011-11-6 22:16 |只看该作者
回复 tmdabc 的帖子
% F8 X4 [; S5 ]  u' K$ ^! u8 V6 w
. D6 C( `5 x' K, L: d4 S& o非常感谢,已经到手了
‹ 上一主题|下一主题 ›
你需要登录后才可以回帖 登录 | 注册
验证问答 换一个

Archiver|干细胞之家 ( 吉ICP备2021004615号-3 )

GMT+8, 2026-11-22 02:53

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.